Matt Nguyen, the company's Vice President of Integrated Healthcare Management, added, "Jim has a proven track record of success. He has developed strong personal relationships with key individuals in the managed care industry and he has helped support the successful launch of several new products during his career. We are excited to have Jim join the team and I am confident he will deliver the most appropriate strategies to ensure reimbursement and contracting success for the launch of h-Patch(TM)."
Mr. Slevin joins the company from CV Therapeutics, where he was responsible for national accounts and was rated top national account manager in 2006. Prior to joining CV Therapeutics, Mr. Slevin held a variety of account management and managed care positions at Kos Pharmaceuticals, Knoll Pharmaceuticals, Sandoz Pharmaceuticals, and Hoechst-Roussel Pharmaceuticals.
About Valeritas, LLC
Valeritas is a medical technology company committed to developing and commercializing innovative drug delivery solutions that directly improve clinical and humanistic outcomes for patients, with an initial focus on the treatment of diabetes.
Valeritas' medical technologies portfolio is headlined by the
h-Patch(TM) insulin delivery system. The h-Patch(TM) is a simple-to-use,
once-daily disposable basal and on-demand bolus delivery system that will
enable the millions suffering from Type 2 diabetes to discreetly and
conveniently deliver insulin throughout the day, including around meals.
Developed to help enhance a patient's glycemic control, the h-Patch(TM) is
the smallest known FDA- cleared insulin delivery system with basal-bolus
capability and no visible needle. The h-Patch(TM) has received FDA 510(k)
clearance, and Phase IV clinical trials are running to support broad
marketing and reimbursement claims. In addition to h-Patch(TM) for the
delivery of insulin, Valeritas' delivery technology portfolio includes
h-Patch(TM) for the delivery of other comp
|SOURCE Valeritas, LLC|
Copyright©2007 PR Newswire.
All rights reserved